We are live on
!
Find out more
Pictet Asset Management Portfolio holdings
AUM
$105B
1-Year Est. Return
38.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+38.07%
3 Year Est. Return
+113.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$90B
AUM Growth
-$2.64B
(-2.9%)
Cap. Flow
+$2.07B
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
17.41%
Holding
2,101
New
60
Increased
1,058
Reduced
623
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$327M |
| 2 |
Broadcom
AVGO
|
+$315M |
| 3 |
Mastercard
MA
|
+$262M |
| 4 |
Intuit
INTU
|
+$226M |
| 5 |
Digital Realty Trust
DLR
|
+$149M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$169M |
| 3 |
WCN
Waste Connections
WCN
|
+$141M |
| 4 |
NextEra Energy
NEE
|
+$134M |
| 5 |
Cadence Design Systems
CDNS
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.36% |
| 2 | Industrials | 16.63% |
| 3 | Healthcare | 13.3% |
| 4 | Financials | 8.12% |
| 5 | Consumer Discretionary | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
MoonLake Immunotherapeutics
MLTX
$1.47B
| $12.6M | 0.01% |
322,114
-24,503
| -7% | -$1.06M |
|
602
Nutrien
NTR
$32.1B
| $12.6M | 0.01% |
253,337
-10,556
| -4% | -$540K |
|
603
Kraft Heinz
KHC
$29.1B
| $12.5M | 0.01% |
412,200
+13,321
| +3% | +$399K |
|
604
iShares 3-7 Year Treasury Bond ETF
IEI
$17.7B
| $12.4M | 0.01% |
105,000
+8,600
| +9% | +$1M |
|
605
Trip.com Group
TCOM
$28.7B
| $12.4M | 0.01% |
194,367
+113,514
| +140% | +$7.43M |
|
|
B
606
Barrick Mining
B
$67.9B
| $12.3M | 0.01% |
633,979
-31,044
| -5% | -$544K |
|
|
XYZ
607
Block Inc
XYZ
$47B
| $12.3M | 0.01% |
225,603
+15,728
| +7% | +$1.17M |
|
608
Principal Financial Group
PFG
$24.4B
| $12.2M | 0.01% |
144,437
-838
| -0.6% | -$69.7K |
|
|
FITB
609
Fifth Third Bancorp
FITB
$52.6B
| $12.1M | 0.01% |
308,628
+3,788
| +1% | +$160K |
|
610
Service Corp International
SCI
$11.5B
| $12.1M | 0.01% |
150,416
+48,586
| +48% | +$3.82M |
|
611
Regency Centers
REG
$13.9B
| $12.1M | 0.01% |
163,456
+21,867
| +15% | +$1.59M |
|
612
NRG Energy
NRG
$25.4B
| $12M | 0.01% |
126,028
-9,405
| -7% | -$951K |
|
613
EQT Corp
EQT
$33.8B
| $11.9M | 0.01% |
223,368
+9,540
| +4% | +$487K |
|
614
Tencent Music
TME
$13.9B
| $11.9M | 0.01% |
827,720
+32,322
| +4% | +$404K |
|
615
Tyler Technologies
TYL
$13B
| $11.9M | 0.01% |
20,428
-441
| -2% | -$262K |
|
616
Molina Healthcare
MOH
$10.8B
| $11.8M | 0.01% |
35,869
-2,128
| -6% | -$643K |
|
617
Krystal Biotech
KRYS
$9.85B
| $11.8M | 0.01% |
65,262
-46,827
| -42% | -$7.88M |
|
618
Cooper Companies
COO
$15B
| $11.7M | 0.01% |
138,881
-6,204
| -4% | -$556K |
|
619
LyondellBasell Industries
LYB
$20.3B
| $11.7M | 0.01% |
166,093
-1,595
| -1% | -$120K |
|
620
Steel Dynamics
STLD
$37.7B
| $11.5M | 0.01% |
92,089
+2,382
| +3% | +$302K |
|
621
C.H. Robinson
CHRW
$17.1B
| $11.5M | 0.01% |
112,346
+23,348
| +26% | +$2.36M |
|
622
Citizens Financial Group
CFG
$31.1B
| $11.5M | 0.01% |
280,657
+2,657
| +1% | +$119K |
|
623
Royalty Pharma
RPRX
$26.4B
| $11.4M | 0.01% |
365,210
+38,838
| +12% | +$1.23M |
|
624
First Citizens BancShares
FCNCA
$25.7B
| $11.3M | 0.01% |
6,116
-260
| -4% | -$530K |
|
625
Labcorp
LH
$26.2B
| $11.3M | 0.01% |
48,457
-485
| -1% | -$118K |
|
Similar funds
Pictet Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Pictet Asset Management held 2,101 positions worth $90B, down 2.9% from $92.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Pictet Asset Management's Q1 2025 filing shows 60 new, 1,058 increased, 623 reduced and 92 closed positions. Its largest new stake was Verona Pharma: 703,063 shares worth $44.6M. The largest sale was Intra-Cellular Therapies Inc., an estimated $187M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Industrials and Healthcare.
- Pictet Asset Management's largest Q1 2025 buy was Verona Pharma: 703,063 shares worth $44.6M.
- Pictet Asset Management added most to Synopsys in Q1 2025, an estimated $327M increase.
- Pictet Asset Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $187M.
- Pictet Asset Management fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q1 2025, selling an estimated $46.5M.
- Pictet Asset Management's ten largest holdings make up 17% of its $90B portfolio in Q1 2025.
- Pictet Asset Management opened 60 new positions and closed 92 in Q1 2025.
- Pictet Asset Management's portfolio value fell 2.9% quarter-over-quarter to $90B.
Based on Pictet Asset Management's 13F filing for Q1 2025, filed 5 May 2025.